| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJM199401133300208 |
| P698 | PubMed publication ID | 7505051 |
| P2093 | author name string | Rittmaster RS | |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 120-125 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Finasteride | |
| P478 | volume | 330 |
| Q34236631 | 5 alpha-Reductase inhibitors |
| Q52561494 | 5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis. |
| Q44086641 | A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women |
| Q77108790 | A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia |
| Q71665330 | A prolactin-secreting tumor in a patient with Klinefelter's syndrome: a case report |
| Q34237246 | A risk-benefit assessment of pharmacological therapies for hirsutism |
| Q53933030 | Androgen deprivation as a strategy for prostate cancer chemoprevention. |
| Q34335616 | Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy |
| Q41579452 | Androgens and prostate cancer: biology, pathology and hormonal therapy |
| Q34544658 | Anti-androgens for the treatment of hirsutism |
| Q41545505 | Antiandrogen and hormonal treatment of acne |
| Q41208689 | Antiandrogen therapy in dermatology |
| Q38529032 | Association of benign prostatic hyperplasia with male pattern baldness |
| Q74425024 | Benign prostatic hyperplasia in older men |
| Q33746068 | Can dietary factors influence prostatic disease? |
| Q48458377 | Changes in expression of the delta subunit of the GABA (A) receptor and in receptor function induced by progesterone exposure and withdrawal. |
| Q36458457 | Chemoprevention of prostate cancer with finasteride |
| Q33943526 | Clinical application of 5alpha-reductase inhibitors |
| Q40572148 | Clinical relevance of testosterone and dihydrotestosterone metabolism in women |
| Q44660551 | Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy |
| Q71917599 | Combined finasteride and flutamide therapy in men with advanced prostate cancer |
| Q32140114 | Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism |
| Q47706800 | Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism |
| Q78067139 | Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism |
| Q74003617 | Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism |
| Q37609189 | Cost-effective therapy in patients with idiopathic hirsutism. |
| Q30011154 | Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study |
| Q35118394 | Drug discovery for alopecia: gone today, hair tomorrow |
| Q71771002 | Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia |
| Q39507404 | Effects of androgen treatment on expression of macrophage Fcgamma receptors |
| Q43993204 | Effects of the chronic use of finasteride on testicular weight and spermatogenesis in Wistar rats |
| Q71812233 | Finasteride and benign prostatic hyperplasia |
| Q45089948 | Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism |
| Q43239383 | Finasteride-related cutaneous vaculitis |
| Q34400464 | GABAA-receptor plasticity during long-term exposure to and withdrawal from progesterone |
| Q38132841 | Hair restoration approaches for early onset male androgenetic alopecia |
| Q32021686 | Hirsutes. II: Treatment |
| Q73249552 | Hirsutism |
| Q46236909 | Hyperglycaemia and reduced risk of prostate cancer |
| Q21089672 | Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia |
| Q77926760 | Indole and benzimidazole derivatives as steroid 5alpha-reductase inhibitors in the rat prostate |
| Q33925053 | Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro |
| Q36065987 | Investigational medications in the treatment of alopecia |
| Q80297806 | Long-Term Experience With 5-alpha-Reductase Inhibitors |
| Q80297775 | Long-Term Experience with 5-alpha-Reductase Inhibitors |
| Q44718278 | Low-dose (2.5 mg/day) finasteride treatment in hirsutism |
| Q34022658 | Management of urinary incontinence |
| Q56429442 | Managing hirsutism in gynaecological practice |
| Q36249876 | New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists |
| Q56341540 | Novel inhibitors of 5α-reductase |
| Q50996127 | Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. |
| Q39454749 | Perception of Hair Transplant for Androgenetic Alopecia |
| Q74444609 | Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers |
| Q48139227 | Physiological modulation of GABA(A) receptor plasticity by progesterone metabolites. |
| Q33671875 | Phytoestrogens and diseases of the prostate gland |
| Q41084868 | Polycystic ovary syndrome: clinical aspects |
| Q34215371 | Production rates of testosterone and of dihydrotestosterone in female pattern hair loss |
| Q36041671 | Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study |
| Q41471860 | Prostate disease in older men: 1. Benign hyperplasia |
| Q47315208 | Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system |
| Q77354257 | Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone |
| Q73376899 | Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia |
| Q35116362 | Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study |
| Q54753532 | The 5alpha-reductase type 1, but not type 2, gene is expressed in anagen hairs plucked from the vertex area of the scalp of hirsute women and normal individuals. |
| Q34190626 | The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies |
| Q44424880 | The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism |
| Q47704410 | Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. |
| Q64982442 | Therapeutic role of androgens in the treatment of osteoporosis in men. |
| Q33736837 | Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy |
| Q39458047 | Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective |
| Q36879271 | Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome |
| Q34530381 | Treatment of hyperandrogenic alopecia in women |
| Q36479670 | Treatment options for benign prostatic hyperplasia. |
| Q44442554 | Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. |
| Q38122628 | Validating therapeutic targets through human genetics |
Search more.